CSI Market
Sign In | Register

Musclepharm (MSLP) Quarterly Cash Flow Statement

Quarterly · GAAP · USD millions
Access MSLP Annual Cash Flow →
This cash flow overview for Musclepharm spans from Mar 31 2021 to Mar 31 2022, illustrating how cash generation and usage have shifted across recent reporting periods.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Quarterly Report, GAAP in USD millions
ITEM 		(Mar 31 2022)
3 Months 		(Dec 31 2021) (Sep 30 2021) (Jun 30 2021) (Mar 31 2021)
Operating Activities
Income-6.30
Depreciation & amortization0.00
Amortization of Other Assets2.65
Increase (Decrease) in Deferred Revenue0.00
Increase (Decrease) in Restructuring Reserve0.00
Provision For Loan Losses Expensed-0.36
Increase (Decrease) in Inventories0.86
R & D, Environmental and Other Expense0.00
Gain (Loss) on Disposition of Property Plant Equipment, Excluding Oil and Gas Property and Timber Property0.00
Share-based Compensation0.44
Income (Loss) from Equity Method Investments0.00
Gains (Losses) on Extinguishment of Debt0.00
Other Stock Based Compensation Expense-
Gain Loss On Derivative Instruments Net Pretax-
Increase Decrease In Fair Value Of Unhedged Derivative Instruments-
Conversion Of Stock Amount Converted-
Stock Issued To Acquire Equipment-
Noncash Or Part Noncash Acquisition Fixed Assets Acquired-
Dividends Payable On Convertible Preferred Stock-
Provision For Reduction Of Doubtful Accounts-
Amortization Of Debt Issuance Costs-
Debt Conversion Original Debt Amount-
Debt Conversion Converted Instrument Warrants Or Options Issued-
Debt Conversion Converted Instrument Amount-
Amortization Of Prepaid Stock Compensation-
Amortization Of Deferred Charges-
Gain Loss On Conversion Of Securities-
Additional Consideration Early Retirement Of Debt-
Provision For Recovery Of Doubtful Accounts-
Amortization Of Prepaid Share Based Compensation Expense-
Amortization Of Prepaid Sponsorship And Endorsement Fees-
Operating Lease Impairment Loss-
Increase Decrease In Prepaid Expenses And Other Current Assets-
Income taxes0.00
Unrealized Gain (Loss) on Securities0.00
Increase (Decrease) in Accounts Receivable-2.53
Increase (Decrease) in Accounts Payable0.90
Increase (Decrease) in Other Accrued Liabilities0.00
Increase (Decrease) in Customer Deposits0.00
Increase (Decrease) in Prepaid Expense-0.01
Other Working Capital-0.47
Other Noncash Expense0.00
Other net0.00
Payments for (Proceeds from) Other Operating Activities1.24
Discontinued operations0.00
Net Cash flow from Operating Activities-3.58
Investing Activities
Capital Expenditures0.00
Sale of Capital Items0.00
Proceeds from Sale and Maturity of Marketable Securities0.00
Payments to Acquire Marketable Securities0.00
Real Estate Investments0.00
Payments Made To Acquire Trademarks-
Payments For Purchase Of Other Assets-
Marketable Securities Gain Loss-
Payment To Acquire Convertible Promissory Note And Warrant-
Trademark Registrations Cost-
Investment In Contract Manufacturer-
Increase (Decrease) in Restricted Cash0.00
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Payments for (Proceeds from) Other Investments0.00
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Acquisition Net of Cash Acquired0.00
Interest in Subsidiaries and Affiliates0.00
Sale of businesses0.00
Accounts payable0.00
Receivables0.00
Payments for (Proceeds from) Other Investing Activities0.00
Other Net0.00
Discontinued operations0.00
Net Cash Flow from Investing Activities0.00
Financing Activities
Short-term debt Net0.00
Other borrowing transactions0.00
Long-term debt - borrowings6.29
Long-term debt - repayments-6.15
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock0.00
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock0.00
Deposits, Annuities, Contract Holders Funds0.00
Other financing activities net0.00
Other net-5.84
Proceeds From Issuance Of Common Stock And Warrants Net-
Proceedes From Foreign Currency Translation Loss-
Proceeds From Issuance Of Paycheck Protection Program Loan-
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations1.22
Payments From Line Of Credit7.37
Proceeds Debt-
Finance Lease Principal Payments-
Payments of Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities2.89
Effect of exchange rate on cash flow0.00
Discontinued operations0.00
Free Cash Flow-3.58
Total Cash Flow-0.69
4 historic quarters locked

Sign in to unlock the full Musclepharm cash flow history.

Sign In Create Free Account

About Musclepharm Corp Quarterly Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC filings and normalized by CSIMarket.

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.
  • Accession: 0001493152-22-013900

Figures are derived from filed reports and may be restated. Historical data is subject to revision.